Medical education in pharmacogenomics-results from a survey on pharmacogenetic knowledge in healthcare professionals within the European pharmacogenomics clinical implementation project Ubiquitous Pharmacogenomics (U-PGx)
Medical education in pharmacogenomics-results from a survey on pharmacogenetic knowledge in healthcare professionals within the European pharmacogenomics clinical implementation project Ubiquitous Pharmacogenomics (U-PGx)
复制标题
DOI：
10.1007/s00228-017-2292-5
复制
发表时间：
2017-10-01
影响因子：
2.9
通讯作者：
Stingl, Julia Carolin
中科院分区：
文献类型：
--
作者：
Just, Katja Susanne;Steffens, Michael;Stingl, Julia Carolin
由于欧洲内部的多样性，药物基因组学测试在临床实践中的实施面临着特定的挑战。在欧洲药物基因组学实施项目“无处不在的药物基因组学”（U-PGx；由欧盟委员会资助）的背景下，我们研究了当前的教育背景。我们开发了一份包含 29 个问题的调查问卷。它已分发给在 U-PGx 项目未来实施地点（奥地利、希腊、意大利、荷兰、斯洛文尼亚、西班牙和英国）工作的医疗保健专业人员，以准备教育计划。此次调查的目的是分析实施地点当前的教育状况。共有 70 名医疗保健专业人员参与了调查。在参与者中，84.3% 的人发现药物基因组学与他们当前的实践相关，但经验仍然很少。超过三分之二 (65.7%) 在过去一年中没有要求或建议进行药物基因组学测试。这主要是由于对药物基因组学的了解不够（40.0%）。确定了应用药物基因组学（识别药物 41.4%，解释测试结果 37.2%）以及强调机制（更好地了解药物代谢 67.1%，更好地了解药物基因组学基本原理 60.0%）的需求。本研究分析了未来用户对药物基因组学的具体态度、经验和教育。人们对药物基因组学测试普遍持积极态度和兴趣。然而，自身经验的程度以及对药物基因组学应用和解释的了解造成了不确定性。因此，教育和培训计划可能有助于在欧洲同一水平上实施药物基因组学。
Due to the diversity within Europe, the implementation of pharmacogenomic testing in clinical practice faces specific challenges. In the context of the European pharmacogenomics implementation project "Ubiquitous Pharmacogenomics" (U-PGx; funded by the European Commission), we studied the current educational background.We developed a questionnaire including 29 questions. It was spread out to healthcare professionals working at the future implementation sites (in Austria, Greece, Italy, Netherlands, Slovenia, Spain and Great Britain) of the U-PGx project in preparation of an educational programme. Aim of the survey was to analyse the current educational situation at the implementation sites.In total, 70 healthcare professionals participated in the survey. Of participants, 84.3% found pharmacogenomics relevant to their current practice, but experience was still rare. More than two-thirds (65.7%) did not order nor recommend a pharmacogenomic test in the past year. This was mainly attributed to not having enough knowledge on pharmacogenomics (40.0%). Needs were identified in application of pharmacogenomics (identifying drugs 41.4%, interpreting test results 37.2%) as well as in underlining mechanisms (better knowledge on drug metabolism 67.1%, better knowledge on basic principles of pharmacogenomics 60.0%).This study analysed the specific attitudes, experience and education on pharmacogenomics of future users. There was a general positive attitude and interest towards pharmacogenomic testing. However, the grade of own experience, and knowledge about application and interpretation of pharmacogenomics caused uncertainty. Thus, education and training programmes may be helpful for implementation of pharmacogenomics at a homogenous level within Europe.